Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Crit Rev Food Sci Nutr ; 62(27): 7576-7590, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-33977840

RESUMEN

Respiratory diseases, both acute and chronic, are reported to be the leading cause of morbidity and mortality, affecting millions of people globally, leading to high socio-economic burden for the society in the recent decades. Chronic inflammation and decline in lung function are the common symptoms of respiratory diseases. The current treatment strategies revolve around using appropriate anti-inflammatory agents and bronchodilators. A range of anti-inflammatory agents and bronchodilators are currently available in the market; however, the usage of such medications is limited due to the potential for various adverse effects. To cope with this issue, researchers have been exploring various novel, alternative therapeutic strategies that are safe and effective to treat respiratory diseases. Several studies have been reported on the possible links between food and food-derived products in combating various chronic inflammatory diseases. Nutraceuticals are examples of such food-derived products which are gaining much interest in terms of its usage for the well-being and better human health. As a consequence, intensive research is currently aimed at identifying novel nutraceuticals, and there is an emerging notion that nutraceuticals can have a positive impact in various respiratory diseases. In this review, we discuss the efficacy of nutraceuticals in altering the various cellular and molecular mechanisms involved in mitigating the symptoms of respiratory diseases.


Asunto(s)
Asma , Broncodilatadores , Antiinflamatorios/uso terapéutico , Suplementos Dietéticos , Humanos , Enfermedad Pulmonar Obstructiva Crónica
2.
J Biochem Mol Toxicol ; 36(10): e23174, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35861662

RESUMEN

Respiratory diseases (RDs), such as chronic obstructive pulmonary disease, cystic fibrosis, asthma, and pneumonia, are associated with significant morbidity and mortality. Treatment usually consists of antibiotics and steroids. Relevant published literature reviews, studies, and clinical trials were accessed from institutional and electronic databases. The keywords used were respiratory diseases, steroids, antibiotics, and combination of steroids and antibiotics. Selected articles and literature were carefully reviewed. Antibiotics are often prescribed as the standard therapy to manage RDs. Types of causative respiratory pathogens, spectrum of antibiotics activity, route of administration, and course of therapy determine the type of antibiotics that are prescribed. Despite being associated with good clinical outcome, treatment failure and recurrence rate are still high. In addition, antibiotic resistance has been widely reported due to bacterial mutations in response to the use of antibiotics, which render them ineffective. Nevertheless, there has been a growing demand for corticosteroids (CS) and antibiotics to treat a wide variety of diseases, including various airway diseases, due to their immunosuppressive and anti-inflammatory properties. The use of CS is well established and there are different formulations based on the diseases, such as topical administration, tablets, intravenous injections, and inhaled preparations. Both antibiotics and CS possess similar properties in terms of their anti-inflammatory effects, especially regulating cytokine release. Thus, the current review examines and discusses the different applications of antibiotics, CS, and their combination in managing various RDs. Drawbacks of these interventions are also discussed.


Asunto(s)
Antibacterianos , Esteroides , Corticoesteroides/uso terapéutico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antiinflamatorios , Citocinas , Esteroides/uso terapéutico
3.
Inflammopharmacology ; 30(3): 725-735, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35316427

RESUMEN

The chronic respiratory non-communicable diseases, asthma and chronic obstructive pulmonary disease (COPD) are among the leading causes of global mortality and morbidity. Individuals suffering from these diseases are particularly susceptible to respiratory infections caused by bacterial and/or viral pathogens, which frequently result in exacerbation of symptoms, lung function decline, frequent hospital emergency visits and increased socioeconomic burden. Human rhinoviruses (HRV) remain the major viral pathogen group implicated in exacerbations of both asthma and COPD. The rhinoviral entry into the host lung epithelium is facilitated primarily by the adhesion site ("receptor") intercellular adhesion molecule-1 (ICAM-1), coincidentally expressed on the respiratory epithelium in these conditions. Multiple observations of increased airway ICAM-1 protein in asthmatics, smokers and smoking-related COPD have been recorded in the literature. However, the lack of robust therapies for COPD in particular has triggered a renewed interest in assessing receptor antagonism-based anti-viral strategies for treatment of intercurrent viral infections in those with pre-existing chronic lung diseases. Given the crucial role ICAM-1 plays in facilitating HRV adhesion and, thus, transmissibility to the host respiratory system, as well as the up-regulation of ICAM-1 by smoking, we summarize the role of HRV in smoking-induced COPD and especially highlight the role of ICAM-1 in epithelial viral adhesion and chronic lung disease progression. Further, the review also sheds light specifically on evolving precision therapeutic strategies in blocking ICAM-1 for preventing viral adhesion and exacerbations of COPD.


Asunto(s)
Asma , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Molécula 1 de Adhesión Intercelular/metabolismo , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Mucosa Respiratoria/metabolismo , Rhinovirus/metabolismo
4.
Rheumatology (Oxford) ; 60(3): 1205-1209, 2021 03 02.
Artículo en Inglés | MEDLINE | ID: mdl-32901283

RESUMEN

OBJECTIVES: Clinical trial data for the efficacy of glucosamine in OA are conflicting. Reportedly, Rotta-manufactured glucosamine products are more likely to be effective, and a possible explanation is greater bioavailability than other brands. Specifically, the aim was to compare the steady-state pharmacokinetics of Rotta- and non-Rotta-manufactured glucosamine products in healthy volunteers and examine the interindividual variability. METHODS: In a crossover design, healthy adult participants ingested 1500 mg/day of a Rotta (DONA powder sachets; imported by Mylan Health, Carole Park, QLD, Australia) and a non-Rotta (glucosamine sulphate 1500 mg one-a-day tablet; Blackmores, Warriewood, NSW, Australia) glucosamine product/brand individually for 6 days. Blood samples were collected immediately before and for 12 h after the ingestion of the last dose of each brand and analysed to determine plasma levels of glucosamine. The pharmacokinetic parameters at steady state [including the minimum (Css min) and maximum (Css max) plasma concentration of glucosamine, time to reach Css max post-dosing (Tss max) and area under the plasma concentration vs time curve (AUCss 0-12)] for each brand were calculated and statistically compared. RESULTS: Fourteen participants [mean age 35.5 years (s.d. 8.8)] were recruited (64.2% males). No significant differences were observed in the pharmacokinetic parameters between the two brands. However, for both brands, the coefficient of variation for Css min, Tss max and AUCss 0-12 exceeded 20%, indicating considerable differences in the parameters between participants. No significant association of the pharmacokinetic parameters was observed with various dosing- and participant-related variables. CONCLUSION: Substantial interindividual differences in the absorption and elimination of glucosamine could be a cause of variable clinical outcomes in OA. TRIAL REGISTRATION: The study was registered with the Australian New Zealand Clinical Trials Registry (http://www.ANZCTR.org.au/ACTRN12618000699268p.aspx), number ACTRN12618000699268p.


Asunto(s)
Glucosamina/farmacocinética , Adulto , Estudios Cruzados , Femenino , Glucosamina/administración & dosificación , Glucosamina/sangre , Humanos , Masculino , Persona de Mediana Edad , Polvos , Comprimidos , Adulto Joven
5.
Future Oncol ; 17(29): 3873-3880, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34263659

RESUMEN

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.


Asunto(s)
Terapia Molecular Dirigida , Medicina de Precisión , Neoplasias de la Próstata/terapia , Proteínas de Unión al ARN/metabolismo , Humanos , Masculino , Neoplasias de la Próstata/patología
6.
Inflammopharmacology ; 29(1): 15-33, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33152094

RESUMEN

Asthma is a common, heterogeneous and serious disease, its prevalence has steadily risen in most parts of the world, and the condition is often inadequately controlled in many patients. Hence, there is a major need for new therapeutic approaches. Mild-to-moderate asthma is considered a T-helper cell type-2-mediated inflammatory disorder that develops due to abnormal immune responses to otherwise innocuous allergens. Prolonged exposure to allergens and persistent inflammation results in myofibroblast infiltration and airway remodelling with mucus hypersecretion, airway smooth muscle hypertrophy, and excess collagen deposition. The airways become hyper-responsive to provocation resulting in the characteristic wheezing and obstructed airflow experienced by patients. Extensive research has progressed the understanding of the underlying mechanisms and the development of new treatments for the management of asthma. Here, we review the basis of the disease, covering new areas such as the role of vascularisation and microRNAs, as well as associated potential therapeutic interventions utilising reports from animal and human studies. We also cover novel drug delivery strategies that are being developed to enhance therapeutic efficacy and patient compliance. Potential avenues to explore to improve the future of asthma management are highlighted.


Asunto(s)
Alérgenos/inmunología , Antiasmáticos/administración & dosificación , Asma/tratamiento farmacológico , Remodelación de las Vías Aéreas (Respiratorias) , Animales , Asma/genética , Asma/inmunología , Sistemas de Liberación de Medicamentos , Humanos , Cumplimiento de la Medicación , MicroARNs/genética
7.
Drug Dev Res ; 80(6): 714-730, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31691339

RESUMEN

Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.


Asunto(s)
Portadores de Fármacos/administración & dosificación , ARN Interferente Pequeño/administración & dosificación , Enfermedades Respiratorias/tratamiento farmacológico , Animales , Humanos
8.
Int J Med Sci ; 15(9): 840-848, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30008595

RESUMEN

Background: The health benefits of probiotics are well established and known to be strain-specific. However, the role of probiotics obtained from different origins and their efficacy largely remains unexplored. The aim of this study is to investigate the in vitro efficacy of probiotics from different origins. Methods: Probiotic strains utilized in this study include Lactobacillus acidophilus DDS-1 (human origin), Bifidobacterium animalis ssp. lactis UABla-12 (human origin), L. plantarum UALp-05 (plant origin) and Streptococcus thermophilus UASt-09 (dairy origin). Screening assays such as in vitro digestion simulation, adhesion, cell viability and cytokine release were used to evaluate the probiotic potential. Results: All strains showed good resistance in the digestion simulation process, especially DDS-1 and UALp-05, which survived up to a range of 107 to 108 CFU/mL from an initial concentration of 109 CFU/mL. Two human colonic mucus-secreting cells, HT-29 and LS174T, were used to assess the adhesion capacity, cytotoxicity/viability, and cytokine quantification. All strains exhibited good adhesion capacity. No significant cellular cytotoxicity or loss in cell viability was observed. DDS-1 and UALp-05 significantly upregulated anti-inflammatory IL-10 and downregulated pro-inflammatory TNF-α cytokine production. All the strains were able to downregulate IL-8 cytokine levels. Conclusion: Of the 4 strains tested, DDS-1 demonstrated superior survival rates, good adhesion capacity and strong immunomodulatory effect under different experimental conditions.


Asunto(s)
Colon/metabolismo , Lactobacillus acidophilus , Probióticos , Línea Celular , Colon/citología , Citocinas/metabolismo , Humanos
9.
Curr Allergy Asthma Rep ; 17(10): 70, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28929391

RESUMEN

Heparin is widely used as an anticoagulant. Currently, this macromolecule is at the forefront in the field of glycobiology because of the recognition of its therapeutic potential in a wide range of medical conditions including inflammation. Heparin is composed of anticoagulant and non-anticoagulant molecules. A large body of evidence suggests that the anti-inflammatory activities of heparin are attributed to its non-anticoagulant molecules and are therefore independent to its anticoagulant effect. However, the potential therapeutic use of heparin in inflammatory conditions is hindered by the presence of anticoagulant molecules causing the risk of bleeding. Therefore, there is an emerging interest in identifying non-anticoagulant molecules of heparin responsible for the anti-inflammatory effects of the parent molecule. The present editorial commentary focuses on the non-anticoagulant applications of heparin for the management of asthma. The commentary concisely describes the plausible mechanisms of action of heparin involved in the therapy of asthma. It also discusses various approaches that are utilised for the development of novel non-anticoagulant analogues of heparin that possess the potent anti-asthmatic activity of the parent molecule but are devoid of anticoagulant effect. We also briefly outline potential future approaches for the use of this molecule as an effective anti-inflammatory agent.


Asunto(s)
Antiinflamatorios/uso terapéutico , Anticoagulantes/uso terapéutico , Asma/tratamiento farmacológico , Heparina/uso terapéutico , Antiinflamatorios/farmacología , Anticoagulantes/farmacología , Asma/patología , Heparina/farmacología , Humanos
10.
Int J Mol Sci ; 18(4)2017 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-28379196

RESUMEN

The endoplasmic reticulum (ER) is a complex protein folding and trafficking organelle. Alteration and discrepancy in the endoplasmic reticulum environment can affect the protein folding process and hence, can result in the production of misfolded proteins. The accumulation of misfolded proteins causes cellular damage and elicits endoplasmic reticulum stress. Under such stress conditions, cells exhibit reduced functional synthesis, and will undergo apoptosis if the stress is prolonged. To resolve the ER stress, cells trigger an intrinsic mechanism called an unfolded protein response (UPR). UPR is an adaptive signaling process that triggers multiple pathways through the endoplasmic reticulum transmembrane transducers, to reduce and remove misfolded proteins and improve the protein folding mechanism, in order to improve and maintain endoplasmic reticulum homeostasis. An increasing number of studies support the view that oxidative stress has a strong connection with ER stress. During the protein folding process, reactive oxygen species are produced as by-products, leading to impaired reduction-oxidation (redox) balance conferring oxidative stress. As the protein folding process is dependent on redox homeostasis, the oxidative stress can disrupt the protein folding mechanism and enhance the production of misfolded proteins, causing further ER stress. It is proposed that endoplasmic reticulum stress and oxidative stress together play significant roles in the pathophysiology of bowel diseases.


Asunto(s)
Estrés del Retículo Endoplásmico , Enfermedades Inflamatorias del Intestino/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Animales , Retículo Endoplásmico/metabolismo , Homeostasis , Humanos , Estrés Oxidativo , Pliegue de Proteína , Transducción de Señal , Respuesta de Proteína Desplegada
12.
Anal Bioanal Chem ; 405(18): 6043-52, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23712644

RESUMEN

It is well known that enoxaparin, a widely used anticoagulant and low-molecular-weight heparin containing a large number of oligosaccharides, possesses anti-inflammatory activity. Whilst enoxaparin has shown promising results in various inflammatory disorders, some of its oligosaccharides have anti-inflammatory properties and others increase the risk of bleeding due to their anticoagulant effects. The aim of this study was to develop an effective ion exchange chromatographic (IC) technique which allows the separation, isolation and, consequently, the identification of different oligosaccharides of enoxaparin with or without anticoagulant activity. The developed method utilises a semi-preparative CarboPac PA100 (9 × 250 mm) ion exchange column with sodium chloride gradient elution and UV detection at 232 nm. The method successfully resolved enoxaparin into more than 30 different peaks. IC-derived oligosaccharides with high, moderate, low or no anticoagulant activity were identified using an anti-factor Xa assay. The anti-inflammatory activity of selected oligosaccharides was investigated using the Griess assay. Using this technique, the oligosaccharides of enoxaparin with low or no anticoagulant activity, whilst exhibiting significant anti-inflammatory activity, could be fractionated. This technique can provide a platform to identify the oligosaccharides which are devoid of significant anticoagulant activity and are responsible for the therapeutic effects of enoxaparin that have been observed in various inflammatory conditions.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Anticoagulantes/farmacología , Cromatografía por Intercambio Iónico/métodos , Enoxaparina/química , Heparina de Bajo-Peso-Molecular/química , Oligosacáridos/aislamiento & purificación , Animales , Secuencia de Carbohidratos , Línea Celular , Cromatografía por Intercambio Iónico/instrumentación , Evaluación Preclínica de Medicamentos/métodos , Enoxaparina/farmacología , Diseño de Equipo , Inhibidores del Factor Xa , Heparina de Bajo-Peso-Molecular/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , Datos de Secuencia Molecular , Peso Molecular , Oligosacáridos/farmacología , Reproducibilidad de los Resultados
13.
Chem Biol Interact ; 351: 109706, 2022 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-34662570

RESUMEN

The challenges and difficulties associated with conventional drug delivery systems have led to the emergence of novel, advanced targeted drug delivery systems. Therapeutic drug delivery of proteins and peptides to the lungs is complicated owing to the large size and polar characteristics of the latter. Nevertheless, the pulmonary route has attracted great interest today among formulation scientists, as it has evolved into one of the important targeted drug delivery platforms for the delivery of peptides, and related compounds effectively to the lungs, primarily for the management and treatment of chronic lung diseases. In this review, we have discussed and summarized the current scenario and recent developments in targeted delivery of proteins and peptide-based drugs to the lungs. Moreover, we have also highlighted the advantages of pulmonary drug delivery over conventional drug delivery approaches for peptide-based drugs, in terms of efficacy, retention time and other important pharmacokinetic parameters. The review also highlights the future perspectives and the impact of targeted drug delivery on peptide-based drugs in the coming decade.


Asunto(s)
Portadores de Fármacos/química , Pulmón/metabolismo , Péptidos/administración & dosificación , Proteínas/administración & dosificación , Administración por Inhalación , Animales , Portadores de Fármacos/administración & dosificación , Humanos , Pulmón/efectos de los fármacos , Enfermedades Pulmonares/tratamiento farmacológico , Nanopartículas/administración & dosificación , Nanopartículas/química , Péptidos/uso terapéutico , Proteínas/uso terapéutico
14.
J AOAC Int ; 104(1): 211-215, 2021 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-33751062

RESUMEN

BACKGROUND: Clinical studies have reported inconsistent outcomes of glucosamine therapy in osteoarthritis patients. One possible reason could be the use of glucosamine products of varying quality. OBJECTIVE: Hence, this study aimed to assess the quality of glucosamine products marketed in Australia and India. This is the first study to investigate both the content and dissolution profiles of glucosamine products. METHOD: The content and dissolution analysis of Australian (n = 25 brands) and Indian (n = 21 brands) glucosamine products was performed according to the criteria specified in the United States Pharmacopoeia (USP). RESULTS: The quality analysis revealed that 16% and 18% of Australian brands, as well as 24% and 19% of Indian brands, did not fulfil the USP content and dissolution criteria, respectively. In approximately half of these cases, the glucosamine content was only slightly below (<3%) that specified by the USP and dissolution was achieved within 15 min after the duration specified by the USP. CONCLUSIONS: The majority of the brands did meet both the content and dissolution analysis criteria of the USP. The extent of deviation from the specified criteria for the other brands was probably insufficient to account for the significant variability in clinical effects. Hence, the study proposed that inter-patient pharmacokinetic variations in glucosamine could be another potential reason for inconsistent therapeutic effects.


Asunto(s)
Glucosamina , Osteoartritis , Australia , Humanos , India , Osteoartritis/tratamiento farmacológico , Solubilidad
15.
Viruses ; 13(7)2021 07 18.
Artículo en Inglés | MEDLINE | ID: mdl-34372603

RESUMEN

The recent coronavirus disease 2019 (COVID-19) outbreak has drawn global attention, affecting millions, disrupting economies and healthcare modalities. With its high infection rate, COVID-19 has caused a colossal health crisis worldwide. While information on the comprehensive nature of this infectious agent, SARS-CoV-2, still remains obscure, ongoing genomic studies have been successful in identifying its genomic sequence and the presenting antigen. These may serve as promising, potential therapeutic targets in the effective management of COVID-19. In an attempt to establish herd immunity, massive efforts have been directed and driven toward developing vaccines against the SARS-CoV-2 pathogen. This review, in this direction, is aimed at providing the current scenario and future perspectives in the development of vaccines against SARS-CoV-2.


Asunto(s)
Vacunas contra la COVID-19/inmunología , COVID-19/inmunología , COVID-19/prevención & control , COVID-19/epidemiología , COVID-19/virología , Humanos , Inmunidad , Inmunidad Colectiva , SARS-CoV-2/aislamiento & purificación , Vacunación
16.
Life Sci ; 283: 119871, 2021 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-34352260

RESUMEN

Non-communicable, chronic respiratory diseases (CRDs) affect millions of individuals worldwide. The course of these CRDs (asthma, chronic obstructive pulmonary disease, and cystic fibrosis) are often punctuated by microbial infections that may result in hospitalization and are associated with increased risk of morbidity and mortality, as well as reduced quality of life. Interleukin-13 (IL-13) is a key protein that regulates airway inflammation and mucus hypersecretion. There has been much interest in IL-13 from the last two decades. This cytokine is believed to play a decisive role in the exacerbation of inflammation during the course of viral infections, especially, in those with pre-existing CRDs. Here, we discuss the common viral infections in CRDs, as well as the potential role that IL-13 plays in the virus-induced disease pathogenesis of CRDs. We also discuss, in detail, the immune-modulation potential of IL-13 that could be translated to in-depth studies to develop IL-13-based therapeutic entities.


Asunto(s)
Gripe Humana/inmunología , Interleucina-13/inmunología , Enfermedades Pulmonares/inmunología , Enfermedad Crónica , Humanos , Inflamación/inmunología , Inflamación/patología , Gripe Humana/patología , Enfermedades Pulmonares/patología , Moco/inmunología
17.
Respir Med ; 176: 106237, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33246296

RESUMEN

The ongoing COVID-19 pandemic has placed a spotlight on infectious diseases and their associations with host factors and underlying conditions. New data on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus are entering the public domain at a rapid rate such that their distillation often lags behind. To minimise weak associations becoming perceived as established paradigms, it is imperative that methodologies and outputs from different studies are appropriately critiqued and compared. In this review, we examine recent data on a potential relationship between smoking and COVID-19. While the causal role of smoking has been firmly demonstrated in regard to lung cancer and chronic obstructive pulmonary disease, such associations have the benefit of decades' worth of multi-centre epidemiological and mechanistic data. From our analysis of the available studies to date, it appears that a relationship is emerging in regard to patients with a smoking history having a higher likelihood of developing more severe symptoms of COVID-19 disease than non-smokers. Data on whether COVID-19 has a greater incidence in smokers than non-smokers is thus far, contradictory and inconclusive. There is therefore a need for some caution to be exercised until further research has been conducted in a wider range of geographical settings with sufficient numbers of patients that have been carefully phenotyped in respect of smoking status and adequate statistical control for confounding factors.


Asunto(s)
COVID-19/complicaciones , COVID-19/epidemiología , Fumar/efectos adversos , Humanos , Factores de Riesgo
18.
Future Med Chem ; 13(6): 543-549, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33538615

RESUMEN

Aim: In the present study, the inhibitory potential of rutin-loaded liquid crystalline nanoparticles (LCNs) on oxidative stress was determined in human bronchial epithelial cells (BEAS-2B) by analysing the expression levels of different antioxidant (NADPH quinine oxidoreductase-1 (NQO1); γ-glutamyl cysteine synthetase catalytic subunit (GCLC)) and pro-oxidant (NADPH oxidase (Nox)-4; Nox2B) genes. Results: Our findings revealed that the rutin-loaded LCNs inhibited the genes, namely Nox2B and Nox4, which caused oxidative stress. In addition, these nanoparticles demonstrated an upregulation in the expression of the antioxidant genes Gclc and Nqo-1 in a dose-dependent manner. Conclusion: The study indicates the promising potential of rutin-loaded LCNs as an effective treatment strategy in patients with high oxidant loads in various respiratory diseases.


Asunto(s)
Cristales Líquidos/química , Nanopartículas/química , Estrés Oxidativo/efectos de los fármacos , Rutina/farmacología , Bronquios/citología , Línea Celular , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Humanos , Lipopolisacáridos/farmacología , NAD(P)H Deshidrogenasa (Quinona)/genética , NAD(P)H Deshidrogenasa (Quinona)/metabolismo , NADPH Oxidasa 2/genética , NADPH Oxidasa 2/metabolismo , Reacción en Cadena de la Polimerasa , Rutina/química , Regulación hacia Arriba/efectos de los fármacos
19.
Clin Transl Immunology ; 10(2): e1247, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33614031

RESUMEN

Inflammation is the result of a complex network of cellular and molecular interactions and mechanisms that facilitate immune protection against intrinsic and extrinsic stimuli, particularly pathogens, to maintain homeostasis and promote tissue healing. However, dysregulation in the immune system elicits excess/abnormal inflammation resulting in unintended tissue damage and causes major inflammatory diseases including asthma, chronic obstructive pulmonary disease, atherosclerosis, inflammatory bowel diseases, sarcoidosis and rheumatoid arthritis. It is now widely accepted that both endoplasmic reticulum (ER) stress and inflammasomes play critical roles in activating inflammatory signalling cascades. Notably, evidence is mounting for the involvement of ER stress in exacerbating inflammasome-induced inflammatory cascades, which may provide a new axis for therapeutic targeting in a range of inflammatory disorders. Here, we comprehensively review the roles, mechanisms and interactions of both ER stress and inflammasomes, as well as their interconnected relationships in inflammatory signalling cascades. We also discuss novel therapeutic strategies that are being developed to treat ER stress- and inflammasome-related inflammatory disorders.

20.
Ther Deliv ; 12(3): 235-244, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33624533

RESUMEN

The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19/prevención & control , Humanos , Pandemias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA